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Abstract MARCKS, a major cellular substrate for protein
kinase C, plays important roles in various cellular functions and
its functions are regulated by calmodulin. We have studied the
conformational properties of recombinant human MARCKS in
solution and in complex with calmodulin. Circular dichroism
(CD) spectra showed a high content of random coil in
physiological solution. When MARCKS or MARCKS-derived
calmodulin-binding peptide was complexed with Ca2+-calmodu-
lin, little change was observed in the CD spectra, suggesting that
MARCKS binds with calmodulin in a non-helical conformation,
which is unique among the calmodulin-binding proteins.
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1. Introduction
Myristoylated alanine-rich C kinase substrate (MARCKS)
is a cellular substrate for protein kinase C as well as for pro-
line-directed protein kinases such as mitogen-associated pro-
tein (MAP) kinase [1^3]. Its precise cellular function remains
unclear, but a recent gene disruption study has indicated that
MARCKS is essential for the normal development of the
central nervous system [4]. MARCKS contains two highly
conserved domains: an N-terminal domain that is modi¢ed
by myristoylation and a basic e¡ector domain in the middle of
the molecule. The latter serves as the calmodulin- and actin-
binding site [5^7]. Phosphorylation by protein kinase C at
four serine residues within the e¡ector domain abolishes
both the calmodulin and actin binding [5]. We have also dem-
onstrated that MARCKS binds to phospholipid membranes
through the N-terminal myristoyl moiety and the basic e¡ec-
tor domain [8]. Phosphorylation of the latter introduces neg-
ative charges, consequently neutralizing its interaction with
acidic phospholipids and facilitating its release from the mem-
brane [8]. Since all the e¡ector molecules compete for the
same binding site, the physiological functions of MARCKS
are regulated in a very complex manner that involves various
components of the signal transduction pathways.
Although rotary shadowing experiments have demonstrated
that MARCKS has an elongated, rod-shaped overall structure
[5], no detailed structural information of the protein was re-
ported. In the present study, we expressed and puri¢ed both
myristoylated and non-myristoylated recombinant human
MARCKS and studied their conformational characteristics by
circular dichroism (CD) spectroscopy. CD spectra suggested
that MARCKS did not have a distinct structure in solution
regardless of the presence of myristoylation. Furthermore,
both MARCKS and a peptide derived from the e¡ector do-
main bound to calmodulin in non-helical conformations.
Thus, MARCKS represents a novel class of calmodulin-bind-
ing proteins, which has a mode of interaction with calmodulin
considerably di¡erent from the known calmodulin-binding
proteins.
2. Materials and methods
2.1. Materials
Dansyl-calmodulin and calmodulin agarose were obtained from
Sigma, while tryptone and yeast extracts were from Difco Ltd. Am-
picillin, kanamycin, and isopropyl-1-thio-L-galactopyranoside (IPTG)
were from Wako Pure Chemical Industries, Ltd. Bovine calmodulin
was either purchased from Wako Pure Chemical Industries or puri¢ed
from bovine brain [9]. Calmodulin concentration was determined
from UV absorption using A276nm (1%, 1 cm) = 1.8. A 25-residue pep-
tide corresponding to the basic e¡ector domain of MARCKS
(KKKKKRFSFKKSFKLSGFSFKKNKK) was synthesized with a
standard t-Boc chemistry using an Applied Biosystems peptide syn-
thesizer 430A. A 20-residue peptide corresponding to the calmodulin-
binding domain of human endothelial nitric oxide synthase (eNOS)
was synthesized as described previously [10,11]. The peptides were
puri¢ed by reversed-phase high-performance liquid chromatography
(HPLC) using a C18 column (Waters WBondasphere 5 W C18-300Aî ,
1.9U15 cm). The peptides were judged to be of greater than 95%
purity by analytical HPLC and electrospray mass spectroscopy. Pep-
tide concentration was determined by quantitative amino acid analy-
sis. The Escherichia coli strain BL21(DE3)pLysS was obtained from
Stratagene. The plasmid pBB131NMT was a gift from Je¡rey I. Gor-
don (Washington University).
2.2. Expression and puri¢cation of non-myristoylated MARCKS
(non-myr MARCKS) and myristoylated MARCKS
(myr MARCKS)
Both non-myr MARCKS and myr MARCKS were expressed in E.
coli, and puri¢ed to homogeneity following the published procedures
[12], the details of which will be published elsewhere (Matsubara et
al., in preparation). The expression and puri¢cation of non-myr
MARCKS were carried out as described previously [12]. For expres-
sion of myr MARCKS, the E. coli strain BL21(DE3)pLysS was co-
transformed with the plasmid pBB131NMT, which contains the gene
encoding yeast NMT [13]. Bacterial culturing was performed similarly
except that 25 Wg/ml kanamycin was added to the media. Coexpres-
sion of MARCKS and NMT was induced by addition of 0.4 mM
IPTG to the log-phase culture. Myr MARCKS was puri¢ed from the
heat-stable protein fractions by calmodulin-agarose chromatography
[14]. The fractions containing myr MARCKS were pooled, concen-
trated/bu¡er exchanged with 20 mM Tris-HCl bu¡er (pH 7.5) with
Centricon 10 and kept frozen at 380‡C until use. Electrospray mass
spectroscopic analysis of the recombinant non-myr MARCKS and
myr MARCKS proteins indicated that the mass di¡erence of the
two proteins was 210 Da, which corresponded very well to protein
myristoylation. Protein concentration was determined by quantitative
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amino acid analysis or by densitometric analysis of the Coomassie
blue-stained SDS gels.
2.3. CD spectroscopy
CD spectra were measured in a Jasco J-720 CD spectropolarimeter
as described previously [10,11]. Spectra were recorded over a 190^260
nm range using a 1-mm quartz cuvette. Temperature was controlled at
25‡C using a water bath. Protein concentration was adjusted to 1 WM
in 20 mM Tris-HCl bu¡er (pH 7.5) containing 0.1 M NaCl and 0.5
mM CaCl2. For CD spectra of the calmodulin-MARCKS protein
complex, equimolar concentrations (1 WM) of calmodulin and
MARCKS were mixed in the same bu¡er. For calmodulin-peptide
complexes, the concentrations of both components were increased to
10 WM. Results are expressed as the mean residue molar ellipticity, [a].
The contents of secondary structures were calculated according to
Green¢eld and Fasman [15].
2.4. Fluorescence measurements
Binding of MARCKS or MARCKS peptide to dansyl-calmodulin
was analyzed in a Jasco FP-777 spectro£uorometer using a 11-cm
quartz cuvette as described previously [11]. With the excitation wave-
length set at 340 nm, emission spectra of dansyl-calmodulin in the
presence or absence of MARCKS or MARCKS peptide were re-
corded in 20 mM Tris-HCl bu¡er (pH 7.5) containing 0.5 mM CaCl2
and indicated concentrations of NaCl. Binding of both MARCKS
and MARCKS peptide to calmodulin was monitored by recording
the £uorescence emission at 490 nm. Dissociation constants of cal-
modulin-MARCKS complexes were determined by a direct ¢t of the
data to the mass equation using a non-linear least squares method
[11].
2.5. Binding of MARCKS peptide to calmodulin-agarose gel
Binding of MARCKS peptide to calmodulin was also determined
by calmodulin-agarose assay [10] in 20 mM Tris-HCl bu¡er (pH 7.5)
containing 0.5 mM CaCl2 and indicated concentrations of NaCl.
After sedimenting the agarose by centrifugation, the supernatant (un-
bound fraction) was removed. The calmodulin-agarose was washed
three times with the same bu¡er, and the bound peptide was eluted
with the SDS sample bu¡er containing 1% SDS. Both unbound and
bound fractions were analyzed by SDS gel electrophoresis.
3. Results
3.1. Conformational properties of myr and non-myr MARCKS
To study the conformational properties of MARCKS, myr
MARCKS and non-myr MARCKS were produced in E. coli.
Coexpression of human MARCKS with or without the yeast
N-myristoyltransferase expression vector in E. coli yielded
myr MARCKS and non-myr MARCKS, respectively. The
proteins were puri¢ed to homogeneity by calmodulin-agarose
chromatography (Fig. 1a). The recombinant myr MARCKS
migrated in a 10% polyacrylamide gel with an apparent mo-
lecular mass of 80 kDa, whereas the recombinant non-myr
MARCKS showed an apparent molecular mass of 68 kDa.
The migrations correspond very well to those of the native
myr and non-myr MARCKS proteins puri¢ed from bovine
brain [16,17]. Since the di¡erence in mass caused by protein
myristoylation is only 210 Da, the shift in migration of about
12 kDa in SDS gel may suggest a conformational change
caused by the myristoyl moiety.
To obtain further information on the protein structures,
CD spectra of myr and non-myr MARCKS were measured
(Fig. 1b). The CD spectrum of myr MARCKS and that of
non-myr MARCKS taken under physiological conditions
showed single negative peaks at around 200 nm, together
with small negative peaks at 220^230 nm, suggesting that
the recombinant proteins have a high content of random
coil structure with a small amount of K-helix. The contents
of secondary structures were calculated to be 5% (K-helix),
28% (L structure), and 67% (random coil) for myr MARCKS.
The content of K-helix (9%) and that of L structure (33%) are
slightly higher in non-myr MARCKS with a corresponding
decrease in random coil content (58%). We have observed a
similar CD spectrum with native MARCKS puri¢ed from
bovine brain [14]. These results suggest that MARCKS has
a so-called natively unfolded structure [18]. Although myr and
non-myr MARCKS showed CD spectra with similar charac-
teristics, the intensity of the negative peak at around 220^230
nm is smaller in myr MARCKS (Fig. 1b). This suggests that
the presence of a myristoyl moiety may a¡ect part of the
three-dimensional structure of MARCKS.
3.2. Conformation of MARCKS in calmodulin complex
Although MARCKS has been previously shown to bind to
calmodulin tightly through the basic e¡ector domain [7,12],
no structural study on MARCKS-calmodulin complex has
been reported. The addition of 150 nM recombinant myr
MARCKS to 50 nM dansyl-calmodulin induced a shift in
the £uorescence emission maximum of dansyl calmodulin
from 510 to 490 nm as well as a 2-fold increase in the intensity
at 490 nm (Fig. 2a), suggesting that the recombinant protein
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Fig. 1. SDS gel electrophoresis and CD spectra of human recombinant myr and non-myr MARCKS. a: Coomassie blue-stained SDS-polyacryl-
amide gel (10%) of myr and non-myr MARCKS. b: CD spectra of 1 WM myr (O) and non-myr (b) MARCKS in 20 mM HCl bu¡er (pH 7.5)
containing 0.1 M NaCl and 0.5 mM CaCl2.
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retained the ability to bind to calmodulin. The dissociation
constant determined by the direct ¢t of titration data to mass
equation was 4.5 þ 0.4 nM (n = 3), a value comparable to
those reported for native and recombinant protein prepara-
tions [7,12]. Non-myr MARCKS has a slightly reduced a⁄n-
ity to MARCKS (data not shown), as has been reported pre-
viously for the native protein [16].
Next, we investigated the secondary structures of
MARCKS in complex with calmodulin by CD spectroscopy.
CD spectra were measured with myr MARCKS mixed with
calmodulin at a 1:1 ratio in the presence of Ca2 or with the
individual component alone. The CD spectra obtained with
MARCKS alone or with calmodulin alone were mathemati-
cally added and the obtained spectrum was compared with the
CD spectrum of the mixture (Fig. 2b). Although the depth of
the large negative peak at 202 nm showed a di¡erence, the
broad peak around 220^230 nm, an indicator of the K-helical
content, did not di¡er signi¢cantly. This implies that the full-
length myr MARCKS binds to calmodulin in a non-helical
structure. This is rather unusual for a calmodulin-binding
protein; an increase in the K-helical content is observed
upon the binding of a target protein to calmodulin. Similar
results were obtained with non-myr MARCKS (data not
shown).
Since the calmodulin-binding site of MARCKS has been
shown to reside in the basic e¡ector domain in the middle
of the molecule, we also studied the conformational character-
istics of the domain in calmodulin complex. When the CD
spectrum of the equimolar complex of the peptide and cal-
modulin was compared to the sum of those of the individual
components, no signi¢cant di¡erence was observed, indicating
that the K-helical content of the peptide did not change sig-
ni¢cantly upon binding with calmodulin. As a comparison,
the calmodulin-binding domain of eNOS, which binds to
calmodulin in a typical K-helical conformation [10], was
used in a similar experiment. The CD spectrum of the cal-
modulin-eNOS calmodulin-binding domain peptide complex
showed an increased negative mean residue ellipticity at 208
and 222 nm (Fig. 2c). This increase in the K-helical content is
due to the formation of an K-helical structure of the peptide
upon calmodulin-peptide complex formation as has been re-
ported for various calmodulin-binding peptides [19]. It is gen-
erally assumed that Ca2-calmodulin itself does not gain sec-
ondary structure when bound to a target peptide, since only
the central helix of calmodulin bends to accommodate the
peptide bound [19]. Therefore, the changes in the K-helical
contents can be attributed mainly to those of the target pep-
tides. These results established that the calmodulin-binding
domain of MARCKS binds to calmodulin in an extended
conformation rather than in an K-helical structure, which is
unique among the calmodulin-binding proteins.
4. Discussion
In the present study, we studied the structural character-
istics of recombinant human MARCKS in solution and in
FEBS 19705 15-1-98
Table 1
Protein sequence resembling the calmodulin-binding domain of MARCKS







MARCKS (human) KKKKKRFSFKKSFKLSGFSFKKNKK 52 24 non-helical this study
F52/MRP (mouse) KKKKFSFKKPFKLSGLSFKRNRK 50 29 non-helical [29]
hDGKj (human)a KKKKRASFKRKSSKKGPEE 53 11 ? [31]
K-Adducin (human) KKKKKFRTPSFLKKSKKKSDS 52 19 ? [32,33]
L-Adducin (human KKKKKFRTPSFLKKSKKEKVES 52 22 ? [33]
35H (rat) KKKKKFRTPSFLKKNKKKSDS 52 19 ? [34]
Ral-A (human)b SKEKNGKKKRKSLAKRIR 56 17 non-helical [30]
eNOS RKKTFKEVANAVKISASLMG 25 40 helical [11]
MLCKc KRRWKKNFIAVSAANRFKKISSSGAL 31 42 helical [19]
aHuman diacylglycerol kinase j. bRas-related GTP-binding protein. cSkeletal muscle myosin light chain kinase.
Fig. 2. Binding of myr MARCKS to calmodulin. a: Fluorescence spectra of 50 nM dansyl-calmodulin in the presence (b) and absence of 150
nM myr MARCKS (F). The excitation wavelength was set at 340 nm. b: CD spectrum of calmodulin-myr MARCKS complex (b), the individ-
ual CD spectra obtained with calmodulin alone and myr MARCKS alone were mathematically added (O). c : CD spectra of calmodulin alone
(b), calmodulin-MARCKS peptide complex (O), and calmodulin-eNOS peptide complex (F).
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complex with calmodulin. The CD spectroscopic studies sug-
gested that MARCKS has a high content of random coil
structure with a small amount of helical structure in solution.
This corresponds very well to the results obtained by physi-
cochemical and rotary shadowing electron microscopic stud-
ies, suggesting that MARCKS has an elongated rod-shaped
structure [5,14,20]. Thus, unlike typical globular proteins,
MARCKS is energetically minimized as unfolded structure.
Recently, this type of protein has been called ‘natively un-
folded protein’ by Weinreb and coworkers [18]. Several na-
tively unfolded proteins contain many structural proteins in
brain, such as MAP2 [21], tau [22] and non-L-amyloid com-
ponent of Alzheimer’s disease (NACP) [23]. Weinreb and
coworkers have suggested that their random coil structure
may be important to facilitate protein-protein interaction.
Since MARCKS also binds to calmodulin, actin and phos-
pholipid membranes, the natively unfolded structure of
MARCKS might be critical for the rapid interactions with
the target macromolecules. A recent report, which demon-
strated that the association of MARCKS e¡ector domain
peptide with membranes is extremely rapid, supports this
idea [24].
We further demonstrated that the binding of both full-
length MARCKS and the e¡ector-binding peptide to cal-
modulin has no observable e¡ect on the overall K-helical
structure of the protein. These results suggest that MARCKS
binds to calmodulin in a non-helical conformation in contrast
to the other typical calmodulin-binding proteins [19]. There-
fore, MARCKS represents a novel class of calmodulin-bind-
ing motif, which has a mode of interaction with calmodulin
considerably di¡erent from the known calmodulin-binding
domains. An extended structure, which is observed as a ran-
dom structure in the CD studies, does not necessary mean
that the domain assumes a £exible random structure. A recent
electron paramagnetic resonance spectroscopic study has in-
dicated that the MARCKS peptide assumes a less £exible
structure in the calmodulin complex compared to a peptide
derived from GAP-43 [25]. The latter contains the so-called
IQ motif that shows a Ca2-independent binding to cal-
modulin, whose mode of interaction with calmodulin is com-
pletely di¡erent from that of the typical calmodulin-binding
proteins [26]. Interestingly, the calmodulin-binding domain of
MARCKS contains more basic amino acid residues (52%) but
fewer hydrophobic amino acids (24%) compared to the typical
calmodulin-binding domains [27,28]. The interaction of the
MARCKS calmodulin-binding domain with calmodulin was
disrupted by increasing the ionic strength (data not shown),
suggesting that the ionic interaction between the basic amino
acids in the calmodulin-binding domain and the acidic resi-
dues of calmodulin plays an important role in the interaction.
This is in contrast to the interaction mode of calmodulin with
other typical calmodulin target proteins, which involves
mainly hydrophobic interactions [19]. The calmodulin-binding
domain of MARCKS, therefore, constitutes a novel class of
calmodulin-binding proteins in terms of structure.
A search in the protein database revealed other calmodulin-
binding proteins with characteristics similar to those of
MARCKS (Table 1). It is apparent that there are sequence
homologies among these proteins. Compared to the conven-
tional calmodulin-binding domains found in eNOS or in my-
osin light chain kinase, they are rich in basic amino acid
residues (often more than 50%) and contain fewer hydropho-
bic amino acid residues. Recent reports on F52 (also called
MARCKS-related protein, MRP) and Ras-related GTP-bind-
ing protein (Ral-A) have shown that these proteins bind to
calmodulin in a non-helical conformation [29,30]. Interest-
ingly, they share not only the structural features but also
several biochemical characteristics. These include predicted
or proven protein kinase C phosphorylation sites and
predicted or proven binding domains of calmodulin, F-actin,
and plasma membranes found in adducin isoforms and
in diacylglycerol kinase [31^34]. This suggests that the
protein sequence motifs common to these proteins may func-
tion as a crosstalk point in various signal transduction path-
ways.
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